TARA at a glance
Protara Therapeutics, Inc. (TARA, SEC CIK 1359931) filed its latest 10-K annual report on March 10, 2026, a 10-Q quarterly report on August 11, 2026, an 8-K current report on August 11, 2026 and Form 4 insider filings as recently as July 1, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- As of June 30, 2026, 28 institutional investment managers tracked by SignalX reported holding Protara Therapeutics, Inc. (TARA) shares worth $70.3 million in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by Shefferman Jesse on June 29, 2026 of 215,687 shares at $4.09 per share.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Insiders · 90 days
- 0 buys · 0 sells
- No open-market trades
- 13F holders
- 28 funds
- $70.3M · +2 vs prior quarter
- Latest 8-K
- Aug 11, 2026
- Item 2.02
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Jun 30, 2026
Management Discussion & Analysis
- Revenue $0, unchanged from $0 YoY; no revenues since inception
- Net loss $21.7M vs $15.0M YoY; operating margin not applicable
- Highest R&D spend TARA-002 NMIBC $6.8M vs $4.9M; lowest TARA-002 LMs $0.9M vs $0.5M
- Cash and securities $161.9M vs $197.9M at December 31, 2025; operating cash use $36.7M
- Near-term milestones: registrational NMIBC enrollment completion Q4 2026; IV Choline interim results Q4 2026; STARBORN-1 completion Q4 2026
Risk Factors
- No material risk-factor changes from the December 31, 2025 Form 10-K
- Clinical development risk carried forward for TARA-002 in NMIBC and LM indications
- Regulatory approval risk carried forward for investigational product candidates
- Competitive biotechnology market risk carried forward amid competing therapies and development programs
- Equity financing and dilution risk from conversion of approximately 2,652 preferred shares into 2,653,351 common shares
AI summary of the TARA 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 2.02: Results of Operations and Financial Condition
- Item 2.02 text contains only an incorporation-by-reference disclaimer
- No earnings figures, reporting-period results, or operating metrics disclosed in the provided text
Item EX-99.1: Item EX-99.1
- Cash, cash equivalents and investments $161.9M at June 30, 2026, expected to fund operations into 2028
- ADVANCED-2 BCG-unresponsive enrollment targeted for 4Q 2026, a key NMIBC registrational milestone
Item 5.02: Departure/Appointment of Directors or Principal Officers
- Chief Medical Officer Leonardo Viana Nicacio resigned effective June 26, 2026 to pursue other opportunities
- Medical leadership responsibilities transferred to Lead Medical Director Carla Beckham
Item 5.07: Submission of Matters to a Vote of Security Holders
- All three Class III nominees elected through 2029, with Cynthia Smith receiving the weakest support at 22.4M votes
- Ernst & Young ratified as independent auditor for fiscal 2026 by 45.0M votes, supporting audit continuity
AI summaries of TARA 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for TARA
Don't miss the next TARA filing
- Alerts as it files. A push when TARA files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut TARA, by share count.
- Ask anything. An AI agent that reads every TARA filing and answers with sources.
TARA alerts on your phone. Follow it in the SignalX Android app.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Shefferman Jesse | G | Jun 30, 2026 | 4,000 | - |
| Shefferman Jesse | G | Jun 30, 2026 | 14,000 | - |
| Shefferman Jesse | G | Jun 30, 2026 | 7,000 | - |
| Shefferman Jesse | G | Jun 30, 2026 | 5,000 | - |
| Shefferman Jesse | M | Jun 29, 2026 | 215,687 | $1.91 |
| Shefferman Jesse | Sell | Jun 29, 2026 | 215,687 | $4.09 |
| Shefferman Jesse | M | Jun 29, 2026 | 215,687 | - |
| BESHAR LUKE M | A | Jun 15, 2026 | 31,000 | - |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Operating Income | -$43.6M | -$49.2M | -$64.5M |
| Net Income | -$40.4M | -$44.6M | -$57.4M |
| Balance Sheet | |||
| Total Assets | - | $181.5M | $209.5M |
| Equity | $68.3M | $167.1M | $196.4M |
| ROE | -59.2% | -26.7% | -29.2% |
| Per Share | |||
| EPS | $-3.57 | $-2.17 | $-1.34 |
| Cash Flow | |||
| Operating CF | -$37.6M | -$35.8M | -$56.4M |
| CapEx | $45K | $63K | $94K |
Source: XBRL data in Protara Therapeutics, Inc. (TARA)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q2 2026Aggregate TARA share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q2 2026 | 28 | $70.3M |
| Q1 2026 | 26 | $86.8M |
| Q4 2025 | 25 | $58.4M |
| Q3 2025 | 23 | $38.2M |
| Q2 2025 | 21 | $25.2M |
| Q1 2025 | 14 | $22.9M |
| Q4 2024 | 11 | $25.5M |
| Q3 2024 | 8 | $2.5M |
- Millennium Management+270.0K (+10%)
- BlackRock+268.5K (+8%)
- Vanguard Capital Management LLC+181.1K (+9%)
- Northern Trust+177.5K (+47%)
- Citadel Advisors LLC+163.8K (+15%)
- Prudential Financial−68.8K (-58%)
- Morgan Stanley−48.5K (-9%)
- Bank of America Corp−43.7K (-5%)
- Marex Group plc−20.0K (-36%)
- PNC Financial Services−4 (-3%)
- Ameriprise Financial+56.3K
- D.E. Shaw & Co+11.1K
Source: 13F-HR filings on SEC EDGAR (aggregated from 156 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
TARA filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 10-Q | Aug 11, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Aug 11, 2026 | - | Analysis | - |
| 4 | Jul 1, 2026 | - | - | - |
| 8-K | Jun 29, 2026 | - | Analysis | - |
| 4 | Jun 16, 2026 | - | - | - |
| 4 | Jun 16, 2026 | - | - | - |
| 4 | Jun 16, 2026 | - | - | - |
| 4 | Jun 16, 2026 | - | - | - |
| 4 | Jun 16, 2026 | - | - | - |
| 4 | Jun 16, 2026 | - | - | - |
| 4 | Jun 16, 2026 | - | - | - |
| 4 | Jun 16, 2026 | - | - | - |
| 8-K | Jun 15, 2026 | - | Analysis | - |
| 8-K | May 13, 2026 | - | Analysis | |
| 10-Q | May 13, 2026 | Mar 31, 2026 | Analysis | |
| SC 13G | Apr 27, 2026 | - | - | |
| 4 | Apr 9, 2026 | - | - | - |
| 4 | Apr 2, 2026 | - | - | - |
| 8-K | Mar 30, 2026 | - | - | - |
| 10-K | Mar 10, 2026 | Dec 31, 2025 | - | |
| 8-K | Mar 10, 2026 | - | Analysis | - |
| SC 13G | Mar 2, 2026 | - | - | |
| 8-K | Feb 24, 2026 | - | Analysis | - |
| 4 | Jan 27, 2026 | - | - | |
| 4 | Jan 27, 2026 | - | - |
Related Health Care companies
- FDMT · 4D Molecular Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
- ADPT · Adaptive Biotechnologies CorpBiological Products, (No Diagnostic Substances)
- ADMA · ADMA BIOLOGICS, INC.Biological Products, (No Diagnostic Substances)
- ALEC · Alector, Inc.Biological Products, (No Diagnostic Substances)
- ALLO · Allogene Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
- AMGN · AmgenBiological Products, (No Diagnostic Substances)
- AVXL · ANAVEX LIFE SCIENCES CORP.Biological Products, (No Diagnostic Substances)
- APGE · Apogee Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
TARA SEC filings: frequently asked questions
Which institutions hold TARA stock?
As of June 30, 2026, the largest Protara Therapeutics, Inc. (TARA) holders among the 13F filers tracked by SignalX were BlackRock ($14.0 million), Millennium Management ($11.8 million), Vanguard Capital Management LLC ($8.8 million), Blackstone Group ($8.7 million), Citadel Advisors LLC ($4.7 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What did TARA report in its latest 8-K?
Protara Therapeutics, Inc. (TARA) filed an 8-K on August 11, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Item 2.02 text contains only an incorporation-by-reference disclaimer.
What are the latest TARA SEC filings?
Protara Therapeutics, Inc. (TARA) filed its latest 10-K annual report on March 10, 2026, a 10-Q quarterly report on August 11, 2026, an 8-K current report on August 11, 2026 and a Form 4 insider filing on July 1, 2026.
What is TARA's SEC CIK number?
Protara Therapeutics, Inc. (TARA)'s SEC Central Index Key (CIK) is 1359931. EDGAR lists every TARA filing under that number.
Ask anything about TARA
The research agent reads TARA's filings, financials, insider trades and 13F holders, then answers with sources.